PMID- 31550810
OWN - NLM
STAT- MEDLINE
DCOM- 20191002
LR  - 20191007
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 99
IP  - 36
DP  - 2019 Sep 24
TI  - [Tailored therapy in treatment of Helicobacter pylori infectionbasedon 
      clarithromycinsensitivity].
PG  - 2826-2830
LID - 10.3760/cma.j.issn.0376-2491.2019.36.006 [doi]
AB  - Objective: To compare eradication rates and compliance of patients with 
      Helicobacter pylori(H. pylori)infection based on clarithromycin sensitivity. 
      Methods: From July 2015 to January 2018,patients with H. pylori infection in 
      Peking university people's hospital were randomly assignedto a 14-day treatment 
      with clarithromycin quadruple therapy versus tailored quadruple therapy for a 
      prospective study. In the group of tailored therapy, medications were adjusted 
      based on clarithromycin sensitivity. In the control group, all patients were 
      given proton pump inhibitors (PPI), amoxicillin, clarithomycin and bismuth. 
      Eradication status was assessed 4 weeks after treatment withurea breath test. 
      Results: The H.pylori eradication rate were higher in the tailor therapy group 
      than that in the control group in intention-to-treat[77.8% vs 65.3%,(P=0.001)] 
      and per,protocol analyses [86.4% vs 70.2%,(P<0.001)], the differences between the 
      two groups were statistically significant.The incidence of compliance between the 
      two groups were also comparable. Conclusions: The tailored therapy basedon 
      clarithromycinsensitivity has a better eradication efficacy and a higher 
      eradication ratesin the patients with H. pylori infection.
FAU - Fan, X
AU  - Fan X
AD  - Department of Gastroenterology, Peking University International Hospital, Beijing 
      102206, China.
FAU - Xue, Q
AU  - Xue Q
AD  - Department of Geriatrics, Peking University People's Hospital, Beijing 100044, 
      China.
FAU - Xian, H P
AU  - Xian HP
AD  - Department ofClinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Sun, Y J
AU  - Sun YJ
AD  - Department ofClinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Zhao, X T
AU  - Zhao XT
AD  - Department ofClinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Wang, J T
AU  - Wang JT
AD  - Department of Geriatrics, Peking University People's Hospital, Beijing 100044, 
      China.
LA  - chi
GR  - Z151100004015418/Beijing Municipal Science & Technology Commission/
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin
MH  - Anti-Bacterial Agents
MH  - Clarithromycin
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Prospective Studies
MH  - Proton Pump Inhibitors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Clarithromycin
OT  - Drug resistance, bacterial
OT  - Helicobacter pylori
OT  - Tailored therapy
EDAT- 2019/09/26 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/09/25 06:00
PHST- 2019/09/25 06:00 [entrez]
PHST- 2019/09/26 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2019.36.006 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2019 Sep 24;99(36):2826-2830. doi: 
      10.3760/cma.j.issn.0376-2491.2019.36.006.